Huntington’s Disease Therapeutics

Huntington’s disease is a hereditary neurodegenerative disease characterized by poor coordination and involuntary body movements. Here is the latest research on Huntington’s disease therapeutics.

July 14, 2020

Therapeutic strategies for Huntington's disease

Current Opinion in Neurology
Carlos Estevez-FragaSarah J Tabrizi
July 27, 2020
Review

Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Deepa Dash, Tiago A Mestre
September 8, 2020
Review

Psychological Interventions for People with Huntington's Disease: A Call to Arms

Journal of Huntington's Disease
Nicolò ZarottiJane Simpson
July 14, 2020
Comment / Editorial
Open Access

AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins

Expert Opinion on Biological Therapy
Melvin M Evers, Pavlina Konstantinova
August 30, 2020
Open Access

mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington's disease

Molecular Brain
Jéssica M de SouzaStephen S G Ferguson
September 15, 2020
Open Access

Rhythmic Haptic Cueing Using Wearable Devices as Physiotherapy for Huntington Disease: Case Study

JMIR Rehabilitation and Assistive Technologies
Theodoros GeorgiouAllan Perry
August 1, 2020
Review
Open Access

Circadian alterations in patients with neurodegenerative diseases: Neuropathological basis of underlying network mechanisms

Neurobiology of Disease
Karim Fifel, Aleksandar Videnovic
June 23, 2020

CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review

Current Pharmaceutical Biotechnology
Sepideh KhatibiSeyed Hamid Aghaee Bakhtiari
August 11, 2020
Open Access

Screening for the C9ORF72 expansion in Greek Huntington Disease phenocopies and controls and meta-analysis of current data

Tremor and Other Hyperkinetic Movements
Dimitrios RikosGeorgia Xiromerisiou
September 1, 2020

Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease

Methods in Molecular Biology
Tejal Aslesh, Toshifumi Yokota
August 28, 2020
Review
Open Access

Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?

Frontiers in Cellular Neuroscience
Cristina Salado-ManzanoJosep M Canals
September 17, 2020
Comment / Editorial
Open Access

Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases

Brain Sciences
Melissa Bowerman
July 14, 2020
Review

Therapeutic antisense oligonucleotides for movement disorders

Medicinal Research Reviews
Epaminondas Doxakis
August 14, 2020

Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

The Journal of Cell Biology
Fred D MastJohn D Aitchison
July 30, 2020
Review

The Role of Neurovascular System in Neurodegenerative Diseases

Molecular Neurobiology
Ajmal AhmadMohammad Moshahid Khan
August 8, 2020

The effect of multidisciplinary therapy on dual task performance in preclinical Huntington's disease: an exploratory study

Annals of Physical and Rehabilitation Medicine
Alvaro ReyesTravis Cruickshank
July 10, 2020
Open Access

Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates

Acta Neuropathologica
Paula García-HuertaClaudio Hetz

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/huntingtons-disease-therapeutics/1d55e83e-caec-46b5-80b6-37e2115dd1c2